JP2022530272A5 - - Google Patents
Info
- Publication number
- JP2022530272A5 JP2022530272A5 JP2021564926A JP2021564926A JP2022530272A5 JP 2022530272 A5 JP2022530272 A5 JP 2022530272A5 JP 2021564926 A JP2021564926 A JP 2021564926A JP 2021564926 A JP2021564926 A JP 2021564926A JP 2022530272 A5 JP2022530272 A5 JP 2022530272A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- acid sequence
- amino acid
- her2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19172329.5 | 2019-05-02 | ||
| EP19172329 | 2019-05-02 | ||
| PCT/EP2020/061850 WO2020221791A1 (en) | 2019-05-02 | 2020-04-29 | Combination of her2 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530272A JP2022530272A (ja) | 2022-06-28 |
| JP2022530272A5 true JP2022530272A5 (enExample) | 2023-04-21 |
| JP7660074B2 JP7660074B2 (ja) | 2025-04-10 |
Family
ID=66625743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564926A Active JP7660074B2 (ja) | 2019-05-02 | 2020-04-29 | Ｈｅｒ２抗体の組み合わせ物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220204644A1 (enExample) |
| EP (1) | EP3962525A1 (enExample) |
| JP (1) | JP7660074B2 (enExample) |
| CN (1) | CN113924116B (enExample) |
| AU (1) | AU2020266253A1 (enExample) |
| CA (1) | CA3137480A1 (enExample) |
| WO (1) | WO2020221791A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4345113A1 (en) | 2022-09-30 | 2024-04-03 | SDS Optic Spolka Akcyjna | Anti-her2 antibody, a nucleic acid molecule encoding the variable region of said antibody, a method of detecting her2 in a biological sample, an immuno-enzymatic elisa assay and use of said anti-her2 antibody or fragments therefof |
| CN117224689B (zh) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | 联合抗her2抗体和化疗剂治疗胃癌的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009042618A1 (en) * | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| BRPI0812682A2 (pt) * | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| CA2800769C (en) * | 2010-05-27 | 2021-11-02 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| KR101453462B1 (ko) * | 2013-05-16 | 2014-10-23 | 앱클론(주) | Her2에 특이적으로 결합하는 항체 |
| WO2016022723A1 (en) * | 2014-08-05 | 2016-02-11 | Merrimack Pharmaceuticals, Inc. | Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies |
| EP3241847A1 (en) * | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Her-2 binding antibodies |
| US20180271996A1 (en) * | 2017-02-28 | 2018-09-27 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| PT3589661T (pt) * | 2017-03-02 | 2024-01-29 | Genentech Inc | Tratamento com adjuvante de cancro da mama positivo para her2 |
-
2020
- 2020-04-29 US US17/606,523 patent/US20220204644A1/en active Pending
- 2020-04-29 WO PCT/EP2020/061850 patent/WO2020221791A1/en not_active Ceased
- 2020-04-29 CA CA3137480A patent/CA3137480A1/en active Pending
- 2020-04-29 EP EP20722571.5A patent/EP3962525A1/en active Pending
- 2020-04-29 CN CN202080032056.9A patent/CN113924116B/zh active Active
- 2020-04-29 AU AU2020266253A patent/AU2020266253A1/en active Pending
- 2020-04-29 JP JP2021564926A patent/JP7660074B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023179713A5 (enExample) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| HRP20240626T1 (hr) | Bispecifična antitijela protiv ceacam5 i cd3 | |
| JP2020152735A5 (enExample) | ||
| JP2019031565A5 (enExample) | ||
| JP2020019787A5 (enExample) | ||
| JP2020522494A5 (enExample) | ||
| JP2015509947A5 (enExample) | ||
| JP2018516969A5 (enExample) | ||
| JP2018501781A5 (enExample) | ||
| JP2019509737A5 (enExample) | ||
| JP2023507190A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JP2015534577A5 (enExample) | ||
| JP2016528251A5 (enExample) | ||
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| JP2017514461A5 (enExample) | ||
| JP2017510559A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2010535713A5 (enExample) | ||
| JP2023545096A5 (enExample) | ||
| JP2006512899A5 (enExample) | ||
| RU2015146664A (ru) | Антитела, способные специфически связываться с her2 | |
| CN115298186B (zh) | 抗psma抗体-依喜替康类似物偶联物及其医药用途 |